Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference34 articles.
1. Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA. 2014;311(4):378–84.
2. EMA. ICH E4 Dose Response Information to Support Drug Registration. ICH Harmonised Tripartite Guideline. 1994.
3. Li DH, Whitmore JB, Guo W, Ji Y. Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials. Clin Cancer Res. 2017;23(1):13–20.
4. Bretz F, Branson M, Pinheiro J. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005;61(3):738–48.
5. EMA. Qualification Opinion of MCP-Mod as an Efficient Statistical Methodology for Model-Based Design and Analysis of Phase II Dose Finding Studies Under Model Uncertainty. Committee for Medicinal Products for Human Use (CHMP). 2014.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献